Table 57:
Scenario Analysis Results, nVNS for Prevention, Cluster Headache
| Scenario | Budget impact, $ milliona | |||||
|---|---|---|---|---|---|---|
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Totalb | |
| Reference case | 0.63 | 1.29 | 1.97 | 2.66 | 3.37 | 9.92 |
| 1: nVNS provided free for the first 93 days | 0.37 | 0.76 | 1.15 | 1.56 | 1.98 | 5.82 |
| 2: Annual uptake of 2% per year, up to 10% in year 5 | 1.26 | 2.58 | 3.94 | 5.32 | 6.75 | 19.84 |
| 3: Annual uptake of 20% per year, up to 100% in year 5 | 12.61 | 25.78 | 39.36 | 53.21 | 67.47 | 198.43 |
| 4a: Cost of the nVNS device decreased by 25% | 0.44 | 0.91 | 1.38 | 1.87 | 2.37 | 6.97 |
| 4b: Cost of the nVNS device increased by 25% | 0.82 | 1.68 | 2.56 | 3.46 | 4.38 | 12.89 |
Abbreviation: nVNS, noninvasive vagus nerve stimulation.
a
In 2024 Canadian dollars.
b
Results may appear inexact due to rounding.